VALARTH See Dr Lal Pathlabs in the appOpen in app
LALPATHLAB · NSE · Healthcare Service Provider

Dr Lal Pathlabs Ltd

What the numbers mean, from its filings and the exchange. Data as of 13 Oct 2026.
Small Cap · AMFI list Jan-Jun 2026 · Vendor sector: Healthcare
fair low confidence No valuation within 120 days; P/E 59.6 vs peers 57.8 (11th of 19).
Statements through FY2026Prices adjusted for 1 corporate actionNot yet reviewed by the adversarial model

What is Dr Lal Pathlabs's share price today?

Dr Lal Pathlabs last traded at ₹1,915.70 on the NSE, as of 13 Oct 2026, 1:00 pm IST, down 2.7% on the day, up 22.2% over a year. Its 52-week range is ₹1,273 to ₹2,039. The live price is in the app.

₹1,915.70 −2.7% today
+22.2% over 1 year · NSE, as of 13 Oct 2026, 1:00 pm IST
60 month-end closes, 31 Oct 2021 to 30 Sep 2026, adjusted for splits and bonuses
52-week range84% of the way up
Low ₹1,273High ₹2,039

What is Dr Lal Pathlabs's market cap?

Dr Lal Pathlabs's market capitalisation is about ₹33,061 crore: what it would cost to buy every share at today's price. That makes it the 25th largest small cap company we cover.

₹33,061 Cr Small Cap25th largest small cap company
Small Cap means the companies ranked 251 and below by size, under SEBI's rules. Shares in issue are worked out from the market cap and the price. What market cap tells you →

Key facts

From the exchange
Symbol
NSE: LALPATHLAB
ISIN
INE600L01024
Cap bucket
Small Cap, 25th largest by market cap
Industry (NSE)
Healthcare › Healthcare Services › Healthcare Service Provider
Listed since
2015
Futures and options
Not traded

Is Dr Lal Pathlabs overvalued?

Fair, with low confidence: no valuation within 120 days; P/E 59.6 vs peers 57.8 (11th of 19).

Valuation

Latest price and trailing 12 months
P/E 59.58
vs peers 57.8 · 11th of 19
Price divided by last year's earnings per share: how many years of today's profit you pay for. Learn more →
P/B Not available
Price divided by book value per share: what you pay for each rupee of net assets on the balance sheet. Learn more →
Market cap ₹33,061 Cr
Total market value of all shares, in ₹ crore. Learn more →
Dividend yield 1.6%
vs peers 0.3% · 1st of 13
Last year's dividends as a share of today's price. Learn more →
PEG (vendor) 35.68
vs peers 18.6 · 11th of 11
P/E divided by the vendor's earnings growth figure, which it does not disclose; a P/E adjusted for how fast profits grow. Learn more →
PEG on our 3-year EPS growth 2.12
P/E divided by the 3-year EPS growth rate from the stored accounts. Learn more →
2 models could be judged
Skipped — Fair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored; Warranted P/B: no P/B

Our valuation range

🔒 Pro
Value range, implied growth at today's price, and the nine models behind it: in the app.

Is Dr Lal Pathlabs a quality business?

Quality score 76.9, 2nd of 19 in its peer set; WATCH on 28 of 30 flags judged.

Quality and risk

Data as of 13 Oct 2026
Business quality Not available
The kind of business, which sets the yardstick it is judged by. Learn more →
Quality score 76.9
vs peers 39.1 · 2nd of 19
Returns, margins, leverage and consistency against its peers, out of 100. Learn more →
Risk level WATCH
28 of 30 flags judged
From flags on debt, earnings quality, dilution and price swings. Learn more →

Profitability

ROE 22.1%
vs peers 10.1% · 1st of 19
Return on equity: profit as a share of shareholders' money. Learn more →
ROCE 27.6%
vs peers 11.7% · 1st of 19
Return on capital employed: operating profit as a share of all the capital in the business, debt and equity. Learn more →
Profit margin 18.1%
vs peers 10.6% · 2nd of 19
Profit after everything, as a share of revenue. Learn more →
EPS ₹30.42
Trailing 12 months
Profit for each share over the last 12 months.

Scorecard

🔒 Pro
Health scores and red flags with their values and history: in the app.
See the scorecard →
Inside the app

Get a sneak peek of Valarth

Start freeStart free
A Valarth stock page: the share price with its chart and 52-week range, valuation and profitability figures, and a scorecard of health checks.
Stock pagePrice, valuation, profitability and a scorecard of health checks for every company, each figure explained.
The Valarth stock screener: a table of companies with price, market cap, P/E, P/B, PEG, EPS and ROE, and filters down the left.
ScreenerEvery listed company, filtered on 212 figures, each with a plain-language lesson beside it.
The Valarth AI Screener answering 'Which companies will benefit from India's Project 75 submarine programme?' with a basket of four naval shipbuilders and a written thesis.
AI ScreenerAsk a question in plain English, like which companies benefit from India's Project 75. It reads the intent, builds the screen and writes the thesis.
A Valarth business-model card for State Bank of India, with a plain-language summary and statements verified against the filing.
Business modelHow a company makes money and what can hurt it, each statement checked against its annual report.
Valarth's Before the Bell edition, with the day's headline, regulator notes and sector moves.
Before the BellA morning edition before the market opens: what moved, which rule changed, and what it means for your holdings.

Has Dr Lal Pathlabs made money for shareholders?

Yes: +22.2% over one year and +1.6% a year over five years.

Shareholder returns

1-year return +22.2%
Price only
What the share price did over the last 12 months. Learn more →
5-year return +1.6% a year
Price only
Yearly average price return over five years, bonuses and splits adjusted. Learn more →
Wealth destroyer Yes
Five-year total return — price CAGR on bonus- and split-adjusted closes plus the dividend yield — below the 7% a bank fixed deposit paid. Learn more →

Returns

3Y and 5Y are yearly averages
1W
+0.3%
1M
+3.3%
3M
+14.2%
6M
+42.8%
1Y
+22.2%
3Y
+18.0%
5Y
+1.6%

Does Dr Lal Pathlabs pay a dividend?

Yes. Dr Lal Pathlabs's dividend yield is 1.56% at the latest price; the last payout was ₹5.00 a share, ex-dividend 30 Jul 2026.

Dividends

Per share, by ex-dividend date
Dividend yield1.56%
The past 12 months' dividends as a share of today's price.
30 Jul 2026 · Interim₹5.00
25 Jun 2026 · Final₹4.00
5 Feb 2026 · Interim 3₹3.50
7 Nov 2025 · Interim 2₹3.50
6 Aug 2025 · Interim₹3.00
Payout ratio🔒 In the app
The share of profit paid out as dividends; a very high share leaves little to reinvest.
Dividend growth, 5 years🔒 In the app
How fast the dividend per share has grown a year.
Years without a miss🔒 In the app
How many years in a row a dividend has been paid.

Is Dr Lal Pathlabs growing?

Revenue 3 years 11.6% a year; profit 3 years 28.3% a year; revenue 5 years 7.0% a year.

Growth

Statements through FY2026 (Mar-26)
Revenue 3 years 11.6% a year
vs peers 16.5% · 17th of 19
Compound annual growth of revenue over three years. Learn more →
Profit 3 years 28.3% a year
vs peers 11.1% · 4th of 19
Compound annual growth of net profit over three years. Learn more →
Revenue 5 years 7.0% a year
Compound annual growth of revenue over five years. Learn more →
Profit 5 years 9.5% a year
Compound annual growth of net profit over five years. Learn more →
EPS 3 years 28.2% a year
Growth in earnings per share, so dilution counts against the company. Learn more →
EPS 5 years 11.5% a year
Growth in earnings per share over five years, so dilution counts against the company. Learn more →
P/E vs own history 1.8%
vs peers -1.7% · 10th of 15
Today's P/E against its own 5-year median; negative is cheaper than its history. Learn more →

How did Dr Lal Pathlabs do last quarter?

Dr Lal Pathlabs reported revenue of ₹798 Cr, up 12.2% on a year earlier and a net profit of ₹170 Cr, up 3.6% in the Jun 2026 quarter.

Latest quarter

Jun 2026
Revenue, latest quarter₹798 Cr
+12.2% on a year earlier
What the company took in over the quarter.
Net profit, latest quarter₹170 Cr
+3.6% on a year earlier
What was left for shareholders after every cost and tax.

How does Dr Lal Pathlabs compare with its peers?

Compared with 18 Healthcare Services (the industry, as the basic industry was too small); 11th of 19 on P/E; 2nd of 19 on quality score.

Compared with 18 Healthcare Services (the industry, as the basic industry was too small)

18 companies

Dr Lal Pathlabs against its peers

Largest 10 of 18 peers, by market cap
CompanyMarket capP/EP/BROEROCE1YQuality 🔒Rank 🔒
Dr Lal Pathlabs Ltd₹33,061 Cr59.6—22.1%27.6%+22.2%
Apollo Hospitals Enterprise Ltd₹1.1 L Cr55.210.716.0%17.5%+1.4%
Manipal Health Enterprises Ltd₹89,321 Cr93.8—6.9%8.4%+1.8%
Max Healthcare Institute Ltd₹84,284 Cr59.010.58.3%10.3%−24.3%
Aster DM Quality Care Ltd₹59,221 Cr113.28.89.6%10.9%−3.0%
Fortis Healthcare Ltd₹57,169 Cr56.66.52.1%4.0%−30.9%
Global Health Ltd₹35,206 Cr63.46.413.2%15.9%−3.9%
Narayana Hrudayalaya Ltd₹34,582 Cr42.812.621.0%18.4%−3.8%
Krishna Institute of Medical Sciences Ltd₹29,577 Cr138.310.211.3%12.6%−1.3%
Dr Agarwals Health Care Ltd₹15,065 Cr101.96.51.9%5.0%−8.5%
Syngene International Ltd₹15,014 Cr63.23.37.7%9.4%−41.3%
Peer median—57.86.510.1%11.7%−1.7%
Market cap in rupees crore; P/E and P/B on the latest price; 1Y is the price return over a year. A dash is a figure that does not apply or is not reported.

Full peer comparison

🔒 Pro
Every peer, every figure, the ranks and the quality and forensic scores side by side: in the app.

Who owns Dr Lal Pathlabs?

Dr Lal Pathlabs is held by promoters 53.2%, foreign institutions 17.4%, domestic institutions 21.6%.

Shareholding pattern

Latest filing, percent of shares
Promoters53.2%
The founders and controlling group.
Foreign institutions17.4%
Overseas funds investing through the FPI route.
Domestic institutions21.6%
Indian insurers, banks, pension and mutual funds together.
Mutual funds18.8%
Indian mutual fund schemes; part of domestic institutions.
Retail and others5.0%
Individual investors and everyone else.
Promoter shares pledged🔒 In the app
Promoter shares given as collateral for loans; a high share is a risk to watch.
Holding trend🔒 In the app
Whether promoters, foreign funds and mutual funds have been adding or selling over recent quarters.

What do analysts say about Dr Lal Pathlabs?

25 analysts cover Dr Lal Pathlabs, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Analyst consensus

25 analysts
ConsensusBuy
The rating most covering analysts give the share.
Average target price🔒 In the app
The mean of the analysts' 12-month price targets.
Upside to target🔒 In the app
How far the target sits above or below today's price.
Share rating it a buy🔒 In the app
The share of covering analysts with a buy rating.

What does Dr Lal Pathlabs do and what is it sensitive to?

Dr Lal PathLabs provides diagnostic testing that patients reach through walk-ins, doctor and hospital referrals, home collection, and a network of collection centres and pick-up points. Sensitive to: seasonality.

Business-model card

FY2026 · 32 verified
1Revenue
4Channels
0Regulators
3Reg. dependencies
4Sensitivities
3Costs
1Geographies

Dr Lal PathLabs provides diagnostic testing that patients reach through walk-ins, doctor and hospital referrals, home collection, and a network of collection centres and pick-up points. The filing reports consolidated revenue of Rs 2,060 Cr for 9M FY26 and PAT of Rs 378 Cr, but does not state how fees are set or split by test type.

Revenue engine

1 verified
Diagnostic services (lab testing)
Interpretation: the company's stated business is diagnostic services; the excerpts do not split revenue by test type or line. Consolidated revenue is Rs 2,060 Cr for 9M FY26 (table).

Customers & channels

4 verified
Walk-in customers
The company states walk-in customers account for the highest share of revenues, so walk-in volume is the largest revenue source; Interpretation: walk-in demand is therefore the most exposed to local footfall.
Doctor and hospital referrals
The company states a single brand pulls patients, meaning referring doctors and hospitals send patients to the brand; Interpretation: referral volume is a separate channel from walk-ins.
Diverse customer pool
The company states its diverse, large customer pool offers monetization opportunities across the channels.
1 more statement
Home collection
Home collection is booked through a dedicated portal, so patients booking home sample pickup are a distinct customer channel.

Regulatory dependencies

3 verified
New Labour Codes statutory impact
A statutory charge from the new Labour Codes was shown as a separate line of Rs 30 Cr in Q3 FY26 and 9M FY26, reducing reported EBITDA margin. Interpretation: changes to labour rules would move the employee cost line, which is Rs 399 Cr for 9M FY26.
Government reporting automation
The company lists RPA for government reporting among its digital capabilities. Interpretation: a change in government reporting requirements would change the cost and workflow of this process.
ABDM participation
The company states it is among the early adopters of ABDM. Interpretation: participation in this national digital health mission links the company's digital systems to a government framework.

Sensitivities

4 verified
Seasonality
The company states there is seasonality in business and quarter results may be influenced by specific occurrences; it advises monitoring on a year-to-date basis. Interpretation: quarterly margins and profits can swing between quarters.
Currency and interest rates
The company lists currency and interest rate movements as factors that could cause results to differ from expectations. Interpretation: direction of impact is not stated.
Macro, government and regulatory trends
The company lists general market, macro-economic, governmental and regulatory trends among factors that could change results. Interpretation: direction of impact is not stated.
1 more statement
Patient volumes and scale
The company states operating margin increased due to economies of scale and cost efficiencies. Interpretation: lower patient volumes would reduce that fixed-cost leverage and compress margin.

Cost inputs

3 verified
Material consumed
Consumables cost line: Rs 129 Cr in Q3 FY26 vs Rs 117 Cr in Q3 FY25; supplier not stated in the excerpts.
Fees to collection centres
Payments to collection centres; Interpretation: this line scales with sample volume collected through the centre network. Rs 294 Cr for 9M FY26.
Employee benefit expenses
Staff cost line: Rs 135 Cr in Q3 FY26 vs Rs 126 Cr in Q3 FY25; Rs 399 Cr for 9M FY26.

Geographies

1 verified
West India (14.0%)
Company states it is consolidating presence in the West through the Suburban acquisition.
Each statement is checked word for word against the FY2026 annual report; the passages are in the app.

What changed recently?

Interim Dividend - Rs 5 Per Share (30 Jul 2026).

Change log

8 entries · newest first
  1. Corporate actionInterim Dividend - Rs 5 Per Share.
  2. Results filedQ1 FY2027 results filed.
  3. Corporate actionDividend - Rs 4 Per Share.
  4. Results filedQ4 FY2026 results filed.
  5. Corporate actionInterim Dividend - Rs 3.50 Per Share.
  6. Results filedQ3 FY2026 results filed.
  7. Corporate actionBonus 1:1; price history adjusted.
  8. Corporate actionInterim Dividend - Rs 7 Per Share.
Get alerts →Sign in to be told when any of these change.

What this page does not tell you

What could not be judged, and why. Never empty.
  • Models not runFair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored; Warranted P/B: no P/B.
  • FlagsWATCH on 28 of 30 flags judged; 1 red; 2 could not be judged.
  • Data gapsP/B, Business quality: not available yet.
Not applicable to this company · 1
  • Altman ZAltman Z is a manufacturing model; a service business has no inventory or plant turnover for it to read.

What this page rests on

✓10 years of annual statements, through FY2026 (Mar-26)✓10 quarters of results✓130 months of month-end prices, adjusted for bonuses and splits (1 corporate action)○no valuation of ours yet✓business-model card FY2026 · 32 verified

Questions people ask

What is Dr Lal Pathlabs's share price today?

Dr Lal Pathlabs last traded at ₹1,915.70 on the NSE, as of 13 Oct 2026, 1:00 pm IST, down 2.7% on the day, up 22.2% over a year. Its 52-week range is ₹1,273 to ₹2,039. The live price is in the app.

What is Dr Lal Pathlabs's market cap?

Dr Lal Pathlabs's market capitalisation is about ₹33,061 crore: what it would cost to buy every share at today's price. That makes it the 25th largest small cap company we cover.

Is Dr Lal Pathlabs Ltd a large cap, mid cap or small cap?

Dr Lal Pathlabs Ltd (LALPATHLAB) is a small cap company in AMFI's classification for Jan-Jun 2026. SEBI's buckets go by rank on six-month average market capitalisation: the top 100 are large caps, 101 to 250 mid caps, the rest small caps.

What is Dr Lal Pathlabs Ltd's P/E ratio?

59.58, vs peers 57.8 · 11th of 19. Price divided by last year's earnings per share: how many years of today's profit you pay for.

Is Dr Lal Pathlabs Ltd overvalued?

Fair, with low confidence: no valuation within 120 days; P/E 59.6 vs peers 57.8 (11th of 19).

How does Dr Lal Pathlabs Ltd make money?

Dr Lal PathLabs provides diagnostic testing that patients reach through walk-ins, doctor and hospital referrals, home collection, and a network of collection centres and pick-up points. The filing reports consolidated revenue of Rs 2,060 Cr for 9M FY26 and PAT of Rs 378 Cr, but does not state how fees are set or split by test type.

Who are Dr Lal Pathlabs Ltd's peers?

Compared with 18 Healthcare Services (the industry, as the basic industry was too small): Apollo Hospitals Enterprise Ltd, Manipal Health Enterprises Ltd, Max Healthcare Institute Ltd, Aster DM Quality Care Ltd, Fortis Healthcare Ltd and 13 more. The app shows how they compare on every figure.

Is this investment advice?

No. Valarth is a research and learning tool and is not a SEBI-registered investment adviser or research analyst. The figures come from the company's filings and the exchanges; what to do with them is your call.

How did Dr Lal Pathlabs do last quarter?

Dr Lal Pathlabs reported revenue of ₹798 Cr, up 12.2% on a year earlier and a net profit of ₹170 Cr, up 3.6% in the Jun 2026 quarter.

Who owns Dr Lal Pathlabs?

Dr Lal Pathlabs is held by promoters 53.2%, foreign institutions 17.4%, domestic institutions 21.6%.

Does Dr Lal Pathlabs pay a dividend?

Yes. Dr Lal Pathlabs's dividend yield is 1.56% at the latest price; the last payout was ₹5.00 a share, ex-dividend 30 Jul 2026.

What do analysts say about Dr Lal Pathlabs?

25 analysts cover Dr Lal Pathlabs, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

More small cap companies

Syrma SGS Technology LtdSYRMA · ₹33,499 CrHimadri Speciality Chemical LtdHSCL · ₹33,373 CrStar Health & Allied Insurance Company LtdSTARHEALTH · ₹33,151 CrKarur Vysya Bank LtdKARURVYSYA · ₹33,085 CrCRISIL LtdCRISIL · ₹32,756 CrKirloskar Oil Engines LtdKIRLOSENG · ₹31,923 CrWockhardt LtdWOCKPHARMA · ₹31,900 CrAegis Vopak Terminals LtdAEGISVOPAK · ₹31,733 Cr
All companies, by market cap →

Everything on Dr Lal Pathlabs, and 6,621 other companies, with 212 filters and the full peer tables

See Dr Lal Pathlabs in the app →See pricing